TORONTO, April 10, 2013 (GLOBE NEWSWIRE) -- Lorus Therapeutics Inc. (TSX:LOR) ("Lorus"), a biopharmaceutical company specializing in the discovery, research and development of pharmaceutical products and technologies for the management of cancer, today announced the presentation of novel biomarker data for its lead cancer therapy LOR-253 at the 2013 Annual Meeting of the American Association for Cancer Research (AACR), held in Washington, DC from April 6 – 10, 2013. The poster presentation titled "Utilization of KLF4 as a pharmacodynamic biomarker for in vivo anticancer activity of a novel small molecule drug LOR-253" will be presented today in the Biomarkers of Drug Response session of the meeting. The abstract for the presentation (Abstract Number: 4649) is available online on the AACR website ( http://www.aacr.org). The poster will be available on the Lorus website following the presentation ( http://www.lorusthera.com ). The presentation covers data from preclinical studies on anticancer activity and tumor biomarker analysis for LOR-253 in animal models of human non-small cell lung cancer (NSCLC). The studies show that LOR-253 has a significant antitumor activity with a dose-response effect in NSCLC that is associated with a dose dependent increase of the tumor suppressor Krüppel-like Factor 4 (KLF4). When tumors are analyzed at different time points following treatment with the same dosing schedule being used in the LOR-253 clinical study, KLF4 protein is significantly increased after eight doses of LOR-253, which corresponds to two treatment cycles in the clinical study. "These data represent an important part of our biomarker strategy for LOR-253, which we believe will translate into the clinic when we examine KLF4 expression in tumor biopsies from patients in the biomarker study," said Dr. Aiping Young, Lorus' President and CEO. "Biomarkers for LOR-253 will be valuable for the interpretation of our clinical data and for optimization of dosing in patients. The findings provide strong evidence to support the use of KLF4 as a biomarker for LOR-253 anticancer activity, and we look forward to sharing these exciting results with the cancer research community at the AACR."